X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The divestment provides Théa with ProQR's late stage ophthalmic assets, QR-110 (sepofarsen) and QR-421a (ultevursen) for patients with rare genetic eye diseases and supports ProQR’s strategic focus on the Axiomer® RNA editing technology platform.
Lead Product(s): Sepofarsen
Therapeutic Area: Rare Diseases and Disorders Product Name: QR-110
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Recipient: ProQR Therapeutics
Deal Size: $186.3 million Upfront Cash: $8.6 million
Deal Type: Divestment December 08, 2023
Details:
Iyuzeh (latanoprost) is a prostaglandin F2α analogue that is believed to reduce the IOP by increasing the outflow of aqueous humor. It is being indicated for primary open-angle glaucoma (POAG) or ocular hypertension (OHT).
Lead Product(s): Latanoprost
Therapeutic Area: Ophthalmology Product Name: Iyuzeh
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 26, 2023
Details:
The divestment provides Théa with ProQR's late stage ophthalmic assets, QR-110 (sepofarsen) and QR-421a (ultevursen) for patients with rare genetic eye diseases and supports ProQR’s strategic focus on the Axiomer® RNA editing technology platform.
Lead Product(s): Sepofarsen
Therapeutic Area: Rare Diseases and Disorders Product Name: QR-110
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Recipient: ProQR Therapeutics
Deal Size: $162.0 million Upfront Cash: $13.7 million
Deal Type: Divestment August 01, 2023
Details:
Iyuzeh (latanoprost) is a prostaglandin F2α analogue that is believed to reduce the IOP by increasing the outflow of aqueous humor. It is being indicated for primary open-angle glaucoma (POAG) or ocular hypertension (OHT).
Lead Product(s): Latanoprost
Therapeutic Area: Ophthalmology Product Name: Iyuzeh
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 03, 2023
Details:
IYUZEH™ is the first and only clinically proven formulation of latanoprost available in the United States that is preservative-free. IYUZEH™ is formulated without any of the preservatives commonly used in topical ocular preparations, including benzalkonium chloride (BAK).
Lead Product(s): Latanoprost
Therapeutic Area: Ophthalmology Product Name: Iyuzeh
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 14, 2022
Details:
Tafluprost Ophthalmic Solution 0.0015% is a prostaglandin analog indicated for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
Lead Product(s): Tafluprost
Therapeutic Area: Ophthalmology Product Name: Tafluprost-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Prasco Laboratories
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 18, 2022
Details:
NVK002 (atropine) is a proprietary, investigational, low-dose, preservative-free atropine eye drop administered nightly as a potential treatment for the progression of myopia in children.
Lead Product(s): Atropine
Therapeutic Area: Ophthalmology Product Name: NVK-002
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Vyluma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 27, 2022
Details:
The agreement represents an expansion of the previously announced exclusive licensing agreement for the commercialization of NVK002 (having Atropine) in Europe and other select countries.
Lead Product(s): Atropine
Therapeutic Area: Ophthalmology Product Name: NVK002
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Vyluma
Deal Size: $150.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement June 14, 2022
Details:
The purchase will add seven established brands, including Akorn’s leading glaucoma therapy, Zioptan®, to Théa’s portfolio. Théa will also welcome Akorn’s nearly 50-person sales force, which Théa expects to expand in support of anticipated growth and launches of additional products in the U.S.
Lead Product(s): Tafluprost
Therapeutic Area: Ophthalmology Product Name: Zioptan
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Akorn Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition January 28, 2022
Details:
Coave and Théa will co-develop CTx-PDE6b under the joint agreement. Coave retains rights to commercialize CTx-PDE6b in the US and Théa receives an exclusive license to commercialize CTx-PDE6b in Europe (EU27), Ukraine, Turkey, Russia and North Africa.
Lead Product(s): CTx-PDE6b
Therapeutic Area: Genetic Disease Product Name: HORA-PDE6b
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Recipient: Coave Therapeutics
Deal Size: $87.3 million Upfront Cash: $11.6 million
Deal Type: Licensing Agreement September 16, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
